Karnataka FDA Cancels 16 Licences, Suspends Pfizer Depot in Counterfeit Drug Crackdown

Karnataka health authorities have cancelled 16 pharmaceutical distribution licences and suspended eight others, including a major depot operated by Pfizer Ltd, following the discovery of an extensive counterfeit drug ring operating near Bengaluru. The ongoing investigation stems from an August 18 raid conducted by the Food Safety and Drugs Administration Drug Enforcement Wing at an unlicensed facility located in Kurubarakeranahalli near Bidadi in the Bengaluru South district.

During the initial operation, enforcement personnel seized suspected counterfeit medicines, packaging equipment, machinery, and forged labels with an estimated market value of approximately Rs 5.05 crore. A Special Investigation Team was subsequently established to examine the broader distribution network. Investigators revealed that cheap, low-cost medications sourced from neighbouring states were allegedly being refilled into fresh vials and relabelled to mimic expensive life-saving pharmaceuticals and imported specialty treatments.

The counterfeiters printed forged labels featuring non-functional scanning codes to deceive buyers. The raid in Karnataka uncovered an interstate counterfeit network that prompted follow-up raids across other Indian states, with suspected counterfeit medicines infiltrating supply chains.

The regulatory crackdown targets a wide network of retail and wholesale pharmaceutical firms accused of handling or distributing the spurious preparations. The Food Safety and Drugs Administration formally cancelled the licences of 16 entities, comprising Avesco Healthcare, Bangalore Speciality Pharma across its general and Chamarajpet outlets, Patel Medi Trade, Rajarajeshwari Pharma, Surya Specialty Pharma, SWS Pharma, Krupa Healthcare, St. Philomena Hospital Drug Centre, Sagar Pharma, Zymus Pharma, Fortune Medical Solutions, Excelcare Pharma, and Patel Medicals.

In addition to the outright cancellations, regulatory authorities suspended eight additional operational licences pending further inquiry. This administrative suspension applies to Med Pharma, Surya Speciality Hospital, Sagar Pharma Unit-II, Vivantha Pharmaceuticals, Maruthi Medicals, Viva Pharma based in Belagavi, Hi-5 Pharma, and the C&F depot of Pfizer Ltd situated in Kempalinganahalli within the Nelamangala taluk of Bengaluru Rural district. State health officials stated that the suspension of the Pfizer facility was enacted due to a lack of cooperation with the Special Investigation Team inquiry rather than any established manufacturing complicity.

The intercepted illicit inventory includes thousands of vials falsely branded under various pharmaceutical names. Authorities recovered 5,640 vials of Cefiavigent 2.5 Injection falsely attributed to Eucratia Healthcare Pvt Ltd, valued at over Rs 3.38 crore, representing the largest single component of the seizure. Officials also documented 1,531 vials of Hizlam Injectables valued at Rs 52.24 lakh and attributed to Welcure Remedies, alongside 264 vials of Emblaveo bearing counterfeit Pfizer labelling valued at Rs 20.59 lakh. Furthermore, the raid uncovered 30 boxes of expired medicines worth Rs 35 lakh intended for possible reintroduction into circulation, alongside batches of Xavitaz, Zavicefta, Tigynt, Tigvnet, Aztreo, and Trezam.

The fraudulent packaging featured QR and scanning codes that regulator verification checks proved to be entirely non-functional. To curtail further circulation, the Food Safety and Drugs Administration has blocked the specific batch numbers associated with the seized stock across its portal. Physical samples have been dispatched to state government laboratories for rigorous chemical analysis to evaluate potency, sterility, and active ingredient composition.

Following the discovery that high-value critical care and cancer treatment products were compromised, health authorities initiated tracking protocols to determine the health status of patients who may have been administered the spurious drugs. Officials are examining distribution logs from hospitals, clinics, and medical stores to trace the exact patient endpoints of the supply chain.

State Health Minister U.T. Khader noted that since counterfeit products are absent from government-run medical institutions, tracking efforts focus on tracing private distribution channels. The Food Safety and Drugs Administration has urged consumers and healthcare practitioners to procure life-saving therapies exclusively through licensed retail pharmacies, insist upon valid tax invoices, and immediately report any packaging anomalies or non-functional verification codes to drug enforcement authorities.

India mandates serialized barcodes or QR codes encoding product identifiers, batch data, and expiry on the top three hundred medicine brands, expanding the rule to cover all anticancer drugs. Counterfeit packaging seized in the Bidadi operation bore forged multinational branding and fake QR codes that failed digital verification.